Our Patients and Families

Supporting A Community Of Patients And Their Families

Our goal is to advance research that enables more people to get diagnoses, treatment and appropriate care. We strive to provide much-needed, practical support and resources to bring hope and relief to patients and their families.

For more information, please visit Dravet Brave.

Frequently Asked Questions

What is Dravet syndrome?

Dravet syndrome is a rare, severe, treatment-resistant epilepsy syndrome with onset in infancy and serious neurodevelopmental, motor, cognitive, and behavioral consequences that persist into adulthood. Studies have reported an incidence rate for Dravet syndrome of approximately one per 16,000 live births with onset occurring within the first year of life.

For more information about the Dravet syndrome Foundation, please go to www.DravetFoundation.org and http://dravet.eu.

What is Lennox-Gastaut syndrome (LGS)?

LGS is a rare, severe form of epilepsy, marked by frequent and prolonged seizures, with peak onset between ages 3 and 5. LGS impacts approximately 14,500 to 18,500 children in the U.S. With currently available treatments, patients continue to struggle to achieve seizure control.

For more information about the LGS Foundation, please go to www.lgsfoundation.org.

What clinical trials are being conducted by Zogenix for rare epilepsies?

Zogenix is currently enrolling patients for clinical studies in LGS. For more information, go to the Fenfluramine Assessment in Rare Epilepsy – https://www.faireprogram.com/lgs-study for more details.

Does Zogenix have an expanded access program?

Learn about the status of accessing our investigational products through expanded access.

Expanded Access Program

Zogenix is committed to developing safe and effective therapies for patients with rare diseases that have limited treatment options.

We understand that patients and families are interested in the availability of our investigational therapy, ZX008 (low-dose fenfluramine hydrochloride) through early access programs. At this stage of clinical development, we believe the best way to help the greatest number of patients is to remain focused on completing our clinical trials to support the earliest possible regulatory approval for ZX008 in intractable epilepsies. Families may consult this website to determine if that status changes in the future. Should we initiate such a program, we will make efforts to alert the epilepsy community and patient groups to the new status.

Should patients, families, or physicians have further questions or require additional information about our clinical trials and development program, please contact our Medical Information department by email at MEDINFO@ZOGENIX.COM or in the United States toll free at 1-866-ZOGENIX